Moderna, Inc. (MRNA) stock analysis
In our weekly check, Moderna, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13.
About Moderna, Inc.
Moderna, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MRNA.
What our checks show for MRNA
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from (debt/equity 0.61).
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The net margin fell by 179 points over 5 years, to -111%: the company keeps less of each sale as profit.
- The gross margin fell by 57.2 points, to 28%: costs are rising faster than prices.
- Weak EPS forecast
- Revenue fell 48.9% a year over the last 3 years.
- Earnings per share fell 30.7% a year over the last 3 years.
- The company is losing money: the net margin is -111%.
- Free cash flow is negative (-77.2% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 104% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 95% from a peak. Would you have held through that?
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
Strengths
- Analysts expect revenue to grow about 18.3% a year over the next years.
- Analysts expect the net margin to improve by 82.8 points from today's -111%.
- A large company: market value $90.38 billion.
- Actively traded: about 22 million shares a day.
Next earnings report: 2027-02-12
Similar companies
REGN · ARGX · VRTX · ONC · RVMD · GMAB
Questions
What grade does Moderna, Inc. (MRNA) have?
In our weekly check, Moderna, Inc. is graded F (A to F). Of 22 checks on debt, profit, cash flow and trend: 7 pass, warnings: 2, red flags: 13. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of MRNA stock?
This week's biggest flags for Moderna, Inc.: High debt, Weak interest cover, Margins falling. In total 15 of 22 checks show a warning or a red flag.
What does Moderna, Inc. do?
Moderna, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as MRNA.
When does Moderna, Inc. report earnings next?
The next earnings report is expected on 2027-02-12. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis